Therapeutic window for striatal dopamine D2/3 receptor occupancy in older patients with schizophrenia: A pilot PET study

American Journal of Geriatric Psychiatry

Volumn 22, Issue 10, 2014, Pages 1007-1016

  Uchida, Hiroyuki ^a,b   Suzuki, Takefumi ^a,b,c   Graff Guerrero, Ariel ^a,c   Mulsant, Benoit H ^a,c   Pollock, Bruce G ^a,c   Arenovich, Tamara ^a   Rajji, Tarek K ^a,c   Mamo, David C ^a,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aging; antipsychotic; dopamine; PET; risperidone; schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; RACLOPRIDE C 11; RISPERIDONE; NEUROLEPTIC AGENT; RACLOPRIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORPUS STRIATUM; DISEASE EXACERBATION; DRUG DOSE REDUCTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MIDDLE AGED; PET SCANNER; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; TREATMENT OUTCOME; CASE REPORT; CLINICAL TRIAL; DOSE RESPONSE; DYSKINESIA; FUNCTIONAL NEUROIMAGING; METABOLISM; SCINTISCANNING;

AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RISPERIDONE; SCHIZOPHRENIA;

EID: 84925245498     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2013.01.045     Document Type: Article

References (34)

1. H. Uchida, T. Suzuki, and D.C. Mamo Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan Am J Geriatr Psychiatry 16 2008 584 593
2. H. Uchida, D.C. Mamo, and B.H. Mulsant Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms J Clin Psychiatry 70 2009 397 405
3. S. Kapur, and D. Mamo Half a century of antipsychotics and still a central role for dopamine D2 receptors Prog Neuropsychopharmacol Biol Psychiatry 27 2003 1081 1090
4. L. Farde, S. Nyberg, and G. Oxenstierna Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients J Clin Psychopharmacol 15 1995 19S 23S
5. S. Kapur, R. Zipursky, and C. Jones Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia Am J Psychiatry 157 2000 514 520
6. Z. Ismail, A.M. Wessels, and H. Uchida Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia Am J Geriatr Psychiatry 20 1 2012 53 60
7. H. Uchida, S. Kapur, and B.H. Mulsant Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms Am J Geriatr Psychiatry 17 2009 255 263
8. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed. 1994 APA Washington, DC
9. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 13 1987 261 276
10. G.S. Alexopoulos, J. Streim, and D. Carpenter Using antipsychotic agents in older patients J Clin Psychiatry 65 suppl 2 2004 5 99
11. L.E. van Beijsterveldt, R.J. Geerts, and J.E. Leysen Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat Psychopharmacology (Berl) 114 1994 53 62
12. G.M. Simpson, and J.W. Angus A rating scale for extrapyramidal side effects Acta Psychiatr Scand Suppl 212 1970 11 19
13. T.R. Barnes A rating scale for drug-induced akathisia Br J Psychiatry 154 1989 672 676
14. W. Guy ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338 1976 U.S. Department of Health, Education, and Welfare Washington, DC
15. O. Mawlawi, D. Martinez, and M. Slifstein Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum J Cereb Blood Flow Metab 21 2001 1034 1057
16. H. Uchida, A. Graff-Guerrero, and B.H. Mulsant Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics Schizophr Res 109 2009 130 133
17. S. Nyberg, L. Farde, and C. Halldin Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients Psychiatry Res 67 1996 163 171
18. Y. Fujimura, H. Ito, and H. Takahashi Measurement of dopamine D2 receptors in living human brain using [11C]raclopride with ultra-high specific radioactivity Nucl Med Biol 37 2010 831 835
19. H. Hall, L. Farde, and C. Halldin Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride Synapse 23 1996 115 123
20. A.A. Lammertsma, and S.P. Hume Simplified reference tissue model for PET receptor studies Neuroimage 4 1996 153 158
21. R.B. Innis, V.J. Cunningham, and J. Delforge Consensus nomenclature for in vivo imaging of reversibly binding radioligands J Cereb Blood Flow Metab 27 2007 1533 1539
22. J.M. Kane, S. Leucht, and D. Carpenter Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary J Clin Psychiatry 64 suppl 12 2003 5 19
23. T. Tsuboi, T. Suzuki, and H. Uchida A tipping point in drug dosing in late-life schizophrenia Curr Psychiatry Rep 13 2011 225 233
24. D.F. Wong, E.P. Broussolle, and G. Wand In vivo measurement of dopamine receptors in human brain by positron emission tomography. Age and sex differences Ann N Y Acad Sci 515 1988 203 214
25. P. Seeman, N.H. Bzowej, and H.C. Guan Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases Neuropsychopharmacology 1 1987 5 15
26. S. Silvestri, M.V. Seeman, and J.C. Negrete Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study Psychopharmacology (Berl) 152 2000 174 180
27. S. Kapur, R.B. Zipursky, and G. Remington 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation Am J Psychiatry 155 1998 921 928
28. S. Nyberg, B. Eriksson, and G. Oxenstierna Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients Am J Psychiatry 156 1999 869 875
29. C.C. Meltzer, J.P. Leal, and H.S. Mayberg Correction of PET data for partial volume effects in human cerebral cortex by MR imaging J Comput Assist Tomogr 14 1990 561 570
30. C. Leroy, C. Comtat, and R. Trebossen Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT J Nucl Med 48 2007 538 546
31. H. Uchida, T.W. Chow, and D.C. Mamo Effects of aging on 5-HT2AR binding: a HRRT PET study with and without partial volume corrections Int J Geriatr Psychiatry 26 2011 1300 1308
32. G. Di Chiara, and A. Imperato Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats J Pharmacol Exp Ther 244 1988 1067 1080
33. R.S. Mackin, K.L. Delucchi, and R.W. Bennett The effect of cognitive impairment on mental healthcare costs for individuals with severe psychiatric illness Am J Geriatr Psychiatry 19 2011 176 184
34. M.B. Adelsky, C.R. Bowie, and T.E. Goldberg Adaptive competence impairment and cognitive deficits in acutely ill schizophrenia patients residing in nursing homes Am J Geriatr Psychiatry 19 2011 752 756